Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
P/E ratio for Ginkgo Bioworks Holdings, Inc. (DNA)
P/E ratio as of 2023: -3.68
According to Ginkgo Bioworks Holdings, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.68. At the end of 2022 the company had a P/E ratio of -1.35.
P/E ratio history for Ginkgo Bioworks Holdings, Inc. from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.68 |
| 2022 | -1.35 |
| 2021 | -6.17 |
| 2020 | -4748.10 |
| 2019 | -5037.86 |
| 2001 | 0.00 |